Chemotherapy before chemoradiation for advanced cervical cancer
Tests chemotherapy given before chemoradiation in adults with advanced cervical cancer.
Plain-language title generated from the registry record
Registry title: Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with newly diagnosed stage IIIC cervical cancer and a large tumour or large lymph node. It tests chemotherapy with albumin-bound paclitaxel and carboplatin before chemoradiation.
- Age
- 18 to 70 years
- Sex
- Women only
- Disease stage
- FIGO (2018) stage IIIC cervical cancer (squamous cell, adenocarcinoma or adenosquamous carcinoma), with a tumour >4 cm (1.6 in) in greatest dimension and/or a lymph node >2 cm (0.8 in) in short axis.
- Earlier treatment
- The cancer must be at initial diagnosis, so no earlier treatment for it.
Main reasons for not taking part
- The cancer is not at initial diagnosis
- Another kind of tumour
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT05367206, who can take part
Where in China
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sun Yat-sen University
- Trial code
- NCT05367206
- Record updated
- 10 May 2022
- Original description
Evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with albumin-bound paclitaxel and carboplatin followed by chemoradiation therapy (CRT) for stage IIIC cervical cancer patients with carcinoma >4 cm in greatest dimension and/or lymph node >2cm in short axis.Read full original descriptionShow less
Department of Radiation, Sun Yat-sen University
Evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with albumin-bound paclitaxel and carboplatin followed by chemoradiation therapy (CRT) for stage IIIC cervical cancer patients with carcinoma >4 cm in greatest dimension and/or lymph node >2cm in short axis.
Inclusion: pathologically comfirmed : squamous cell, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix；; FIGO (2018 International Federation of Gynecology and Obstetrics) stage IIIC with carcinoma >4 cm in greatest dimension and/or lymph node >2 cm in short axis at initial diagnosis; age 18 to 70 years；; Eastern Cooperative Oncology Group performance status 0 to 2；; adequate organ function.
Exclusion: not at initial diagnosis; 2. with other kind of tumor; -.